<DOC>
	<DOCNO>NCT02314403</DOCNO>
	<brief_summary>This study examine safety effectiveness combination kidney bone marrow transplant haplo-identical relate donor . An investigational medication treatment give prior transplant help protect transplant kidney attack body 's immune system</brief_summary>
	<brief_title>Renal Allograft Tolerance Through Mixed Chimerism ( Belatacept )</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Male female 1860 year age Candidate livingdonor renal allograft HLA mismatch donor First second transplant either live donor cadaveric transplant first transplant . Use FDAapproved method contraception recipient time study treatment begin 104 week ( 24 month ) renal transplantation . Ability understand provide inform consent . Serologic evidence prior exposure EBV . ABO blood groupincompatible renal allograft . Evidence antiHLA antibody within 60 day prior transplant assessed routine methodology ( AHG and/or ELISA ) Leukopenia thrombocytopenia . Positive HIV1 , hepatitis B core antigen , hepatitis C virus ; positivity hepatitis B surface antigen . Cardiac ejection fraction &lt; 40 % clinical evidence insufficiency . Forced expiratory volume FEV1 &lt; 50 % predict . Lactation pregnancy . History cancer basal cell carcinoma skin carcinoma situ cervix . Underlying renal disease etiology high risk disease recurrence transplant kidney ( focal segmental glomerulosclerosis , type I II membranoprolifertive glomerulonephritis ) . Prior doselimiting radiation therapy . Known genetic disease family history may result great sensitivity effect irradiation , physical deformity would preclude adequate shield appropriate dose irradiation component condition regimen . Enrollment investigational drug study within 30 day prior enrollment . Abnormal ( &gt; 2 time lab normal ) value ( ) liver function chemistry ( ALT , AST , AP ) , ( b ) bilirubin , ( c ) coagulation study ( PT , PTT ) . Allergy sensitivity component belatacept , ATG , tacrolimus , rituximab . Maintenance immunosuppression within 3 month prior condition physiological dos steroid , define â‰¤ 50 mg hydrocortisone dose equivalent . The presence medical condition investigator deem incompatible participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ESRD</keyword>
</DOC>